



4 March 2026

## ASX Announcement

### Control Bionics Secures German Statutory Reimbursement Listing for NeuroNode

Control Bionics Limited (ASX: CBL) (“CBL” or “the Company”) is pleased to announce that its NeuroNode® device has been formally included in the German Statutory Health Insurance Medical Aids Directory (Hilfsmittelverzeichnis) under §139 SGB V.

The decision, issued by the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds), confirms that NeuroNode has met all regulatory, safety, quality and clinical requirements for **reimbursement eligibility** within Germany’s statutory health insurance system.

NeuroNode has been assigned Position Number: 16.99.04.1013 – NeuroNode – PL-27-1000.

### Why This Matters

Germany represents the **largest assistive technology market in Europe** and one of the most structured reimbursement systems globally. Inclusion in the Hilfsmittelverzeichnis:

- **Enables reimbursement** eligibility across Germany’s statutory health insurance funds;
- **Removes a key commercial barrier** for distributor engagement;
- **Provides validation** of safety, functionality and quality standards; and
- Positions CBL **to scale its NeuroNode** only distribution strategy across the German speaking region.

This approval follows CE compliance and confirms that NeuroNode satisfies German-language information and quality requirements.

### What Happens Now

With reimbursement eligibility secured, the Company will now:

#### 1. Appoint and Activate Distribution

CBL will prioritise securing a German distribution partner with established relationships across speech therapy, rehabilitation clinics and statutory insurers.

#### 2. Submit Pricing and Contracting Applications

Distributors will work directly with health insurers and regional procurement bodies to establish pricing schedules consistent with the assigned product code.

#### 3. Commence Pilot Installations

Initial demonstration stock and clinician training programs will be deployed to key reference sites to accelerate adoption.

#### 4. Leverage NeuroNode-Only Strategy

The German listing supports CBL's global pivot toward NeuroNode-only wholesale distribution, reducing reliance on direct-to-consumer AAC sales and enabling scalable partner-led growth.

#### **CEO Commentary**

CBL CEO Jeremy Steele said:

"Inclusion in the German statutory reimbursement directory is a significant milestone for Control Bionics. Germany is the largest assistive technology market in Europe and a gateway into the broader EU region."

"This approval materially lowers the barrier to entry for distribution partners and supports our strategy of building a scalable NeuroNode-only wholesale business globally."

#### **Strategic Implications**

This approval:

- Strengthens CBL's European market entry;
- Supports future expansion into Austria and Switzerland;
- Enhances distributor negotiations in other EU markets; and
- Provides additional validation in ongoing global discussions.

The Company will update shareholders as distribution agreements are executed and first commercial shipments commence.

This announcement has been authorised for release by the Board of Control Bionics Limited.

For further information, please contact:

#### **Investors and Media:**

Jeremy Steele – CEO and Managing Director  
[jsteele@controlbionics.com](mailto:jsteele@controlbionics.com)

Brett Crowley - Company Secretary  
[brettcrowley@controlbionics.com](mailto:brettcrowley@controlbionics.com)

For further information visit the website: <https://www.controlbionics.com/>

For personal use only

### **About Control Bionics:**

Control Bionics is a Neurotechnology medical device company that has more than 20 years' experience in the development and use of surface Electromyography (EMG) devices.

### **About NeuroNode:**

Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

### **About NeuroStrip:**

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Europe and Japan.

For personal use only